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ABSTRACT
Curcumin has been known to have a variety of biological activities in different diseases,
including inflammation, cancer, and diabetes. The limited bioavailability of curcumin is due to
its low solubility and extensive metabolism, rendering curcumin unusable as an oral therapeutic
agent. The aim of the study is to enhance the solubility and bioavailability of curcumin by
preparing curcumin-piperine solid dispersion (SD) utilizing the hot-melt extrusion technique.
Three physical mixtures with different ratios were prepared as following: F1 (5% w/w piperine,
15% w/w curcumin, 80% w/w Soluplus®), F2 (10% w/w piperine, 30% w/w curcumin, 60%
w/w Soluplus®), and F3 (15% w/w piperine, 45% w/w curcumin, 40% w/w Soluplus®). The
extrusion process was conducted using two different extrusion temperatures, 130 °C and 140 °C,
to study the effect of temperature on physicochemical properties. Differential scanning
calorimetry (DSC) was used to obtain the thermal characterization of the extrudates with a
heating rate of 10 °C/min, ranging 20 to 200 °C. Additionally, Fourier transform infrared
spectroscopy (FTIR) was performed to evaluate the chemical interaction between the
components. Surface morphologies of the extrudates were analyzed utilizing the scanning
electron microscope. Drug release studies for the pure compounds and the extrudates were
performed using the USP apparatus II, and the samples were analyzed using high-performance
liquid chromatography (HPLC).
Curcumin-piperine solid dispersion was successfully prepared by the hot-melt extrusion
technology. DSC results showed the presence of endothermic peaks, one for curcumin at 179 °C,
and another for piperine at 132 °C. However, these peaks were not observed in the extrudates’

ii

thermograms, indicating the solubilization of curcumin and piperine within the polymeric carrier
at an amorphous state. The formation of hydrogen bonds between the components was observed
in the FTIR spectra. Results from drug release studies showed enhancements in curcumin release
profiles for up to 9-folds in the formulations, compared to pure curcumin.

iii

DEDICATION
I would like to dedicate this work to my lovely wife for her unlimited support and guidance in
every aspect of my life, to my parents who have raised me to be the person I am today, and to my
son Azzam.

iv

ACKNOWLEDGEMENTS
I would like to express my deepest gratitude to Professor Michael Repka and Professor Eman
Ashour for their support, advice, and understanding throughout my journey. It was an honor
working with them. Also, I would like to thank Professor Mahavir Chougule for his time and
effort as a committee member. Special thanks go to my friends and lab colleagues Mashan
Almutairi, Ahmed Almotairy, Sandeep Sarabu, Arun Butreddy, and Mohammed Alyahya for
their support. Last but not the least, I would like to thank Dr. Manjeet Pimparade for his time and
effort as an external reviewer.

v

TABLE OF CONTENTS
Abstract .......................................................................................................................... ii
Dedication...................................................................................................................... iv
List of Abbreviations and Symbols.................................................................................. v
Acknowledgments ......................................................................................................... vii
List of Tables ................................................................................................................. xi
List of Figures ............................................................................................................... xii
1. Introduction ......................................................................................................... 1
1.1. Solubility improvement of poorly soluble drugs ............................................ 1
1.2. Solid dispersion ............................................................................................ 2
1.3. The hot-melt extrusion technique .................................................................. 4
1.4. Model compounds ........................................................................................ 6
1.4.1. Curcumin ........................................................................................... 6
1.4.2. Piperine .............................................................................................. 7
1.5. Objectives ..................................................................................................... 8
2. Methodology ....................................................................................................... 9
2.1. Materials ....................................................................................................... 9
2.2. Methods ........................................................................................................ 9
2.2.1. Hot-melt extrusion ............................................................................. 9
2.2.2. Differential scanning calorimetry (DSC) .......................................... 11
2.2.3. Scanning electron microscopy (SEM)............................................... 11

vi

2.2.4. Fourier transform infrared spectroscopy (FTIR) ............................... 12
2.2.5. Drug content .................................................................................... 12
2.2.6. In-vitro drug release studies.............................................................. 12
2.2.7. Stability studies ................................................................................ 13
3. Results and Discussion ...................................................................................... 14
3.1. Hot-melt extrusion ...................................................................................... 14
3.2. Differential scanning calorimetry (DSC) ..................................................... 15
3.3. Scanning electron microscopy (SEM) ......................................................... 18
3.4. Fourier transform infrared spectroscopy (FTIR) .......................................... 20
3.5. Drug content ............................................................................................... 22
3.6. In-vitro drug release studies ........................................................................ 23
3.7. Stability studies........................................................................................... 30
4. Conclusion and Future Directions ...................................................................... 31
List of References ......................................................................................................... 32
VITA ............................................................................................................................ 37

vii

LIST OF TABLES
1. The biopharmaceutical classification system (BCS).................................................................2
2. Examples of commercially available solid dispersions ............................................................2
3. Types of solid dispersion .........................................................................................................3
4. Advantages and disadvantages of HME ...................................................................................5
5. Composition of the three formulations................................................................................... 10
6. Parameters of the hot-melt extrusion process ......................................................................... 11
7. The percent drug content of curcumin ................................................................................... 23
8. The percent drug content of piperine ..................................................................................... 23
9. Similarity factor calculation for curcumin.............................................................................. 28
10. Dissolution kinetic calculations……………………………………………………………...29

viii

LIST OF FIGURES
1. A schematic for the hot-melt extrusion process ........................................................................6
2. The chemical structure of curcumin ........................................................................................7
3. Standard screw configuration ................................................................................................ 10
4. Physical appearance of the extrudates .................................................................................... 15
5. Thermogram of pure curcumin, pure piperine, and Soluplus® ................................................ 17
6. Thermogram of the physical mixtures of the three formulations ............................................ 17
7. Thermogram of the three formulations .................................................................................. 18
8. SEM images for formulation F1 with different extrusion temperatures .................................. 19
9. FTIR analysis of the three formulations ................................................................................. 21
10. The release profiles for F1 formulations .............................................................................. 25
11. The release profiles for F2 formulations .............................................................................. 26
12. The release profile for F3 formulations ................................................................................ 27

ix

1. INTRODUCTION
1.1. Solubility improvement of poorly soluble drugs:
The oral bioavailability of a drug relies on several factors including aqueous solubility,
dissolution rate, drug permeability, first pass metabolism, and pre-systemic metabolism. Drug
solubility is a key factor to achieve the desired concentration of a drug in the blood circulation
that is required to produce a pharmacological effect. Moreover, drug solubility is considered a
major challenge during the drug development process.
In recent years, several technologies have emerged in the pharmaceutical field to develop new
drugs with high affinity and selectivity for their targets. Computational modeling, high
throughput screening, and combinatorial chemistry are examples. However, a drawback of such
strategies is that the synthesized drug tends to have a low bioavailability (1).
Interestingly, it has been reported that 50% of the discovered and synthesized drugs are
classified as class II under the biopharmaceutical classification system (poorly water-soluble
drugs, Table 1) (2). According to the U.S pharmacophobia, the drug is water-soluble when the
maximum dose is soluble in 250 ml of aqueous media with pH range of 1 to 7.5 (3). In order to
overcome the solubility barrier, several techniques have been applied to enhance the drug
solubility and increasing the bioavailability. These include solid dispersion, salt formation,
crystal engineering, particle size reduction, complexation, and so forth (4).
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Table 1. The biopharmaceutical classification system (BCS)
Class

Solubility

Permeability

I

High

High

II

Low

High

III

High

Low

IV

Low

Low

1.2. Solid dispersion:
Solid dispersion is a strategy to enhance drug solubility, dissolution rate, and
bioavailability. With the increase in numbers of poorly water-soluble drugs, solid dispersion has
been vigorously investigated as an approach to overcome the limitations of many drugs. Several
solid dispersion formulations have been approved and marketed, indicating the effectiveness of
this approach (Table 2) (5). The concept of solid dispersion is based on the combination of at least
two different components, a hydrophobic drug and a hydrophilic carrier, in which the
hydrophobic drug is dispersed in the hydrophilic carrier at a solid-state.

Table 2. Examples of commercially available solid dispersions.
Brand Name

Manufacturer

Drug

Gris-PEG

Pedinol Pharmacal Inc.

Griseofulvin

Kaletra

Abbott

Lopinavir, ritonavir

Intelence

Tibotec

Etravirin

Certican

Novartis

Everolimus

Cesamet

Valeant Pharmaceuticals

Nabilone
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The classification of solid dispersions mainly depends on the physical state of the
polymeric carrier (crystalline or amorphous) and the way that the drug is dispersed in the matrix.
Three different types of solid dispersions can be prepared by utilizing crystalline matrix: eutectic,
amorphous precipitates in a crystalline matrix, and solid solution. Whereas, glass suspension and
glass solution can be achieved using an amorphous matrix (Table 3) (6) .

Table 3. Types of solid dispersion.
Type of solid dispersion

Matrix

Drug

Eutectic

Crystalline

Crystalline

Amorphous precipitate in crystalline matrix

Crystalline

Amorphous

Solid solutions

Crystalline

Molecularly dispersed

Glass suspension

Amorphous

Crystalline

Glass suspension

Amorphous

Amorphous

Glass solution

Amorphous

Molecularly dispersed

Modifying the physical state and reducing the particle size of the drug are advantages of
using the solid dispersion approach (5). The solubility and the bioavailability of poorly watersoluble drugs will also be improved (5). According to the Noyes-Whitney equation (equation 1),
the reduction in the particle size can improve drug wettability and reduce particle agglomeration
by increasing the surface area in contact with the dissolution media. Moreover, changing the
physical state of the drug to a high free energy state (an amorphous state) can enhance drug
solubility, since no energy is required to break the crystal lattice during the dissolution (7).
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𝑑𝑀
𝑑𝑡

= 𝐴𝐷(𝐶𝑆 − 𝐶𝑡)/ℎ

(Equation 1)

Where:
dM/dt = the dissolution rate
A = the specific surface area
D = the diffusion coefficient
Cs = the saturation solubility
Ct = drug concentration at time t
h = the diffusion layer thickness

1.3. Hot-melt extrusion:
Different techniques have been applied to prepare solid dispersion formulations,
including hot-melt extrusion, spray drying, melt fusion, and the supercritical fluid technique.
Hot-melt extrusion (HME) is an efficient and successful technique for manufacturing
pharmaceutical products. In the 1980s, HME was first introduced in the pharmaceutical industry,
and before that, it was used in food and plastics industries.
HME is the solution for several pharmaceutical challenges, including poor solubility, insufficient
stability, unpalatable taste, and manufacturing of films. As any pharmaceutical technique, HME
comes with a few disadvantages, especially for heat-sensitive drugs (Table 4) (8).
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Table 4. Advantages and disadvantages of HME
Advantages

Disadvantages

Continuous processing

Temperature

Few processing steps

Not suitable to process heat-sensitive drugs

Solvent free
Low cost
Easy to scale-up
High throughput

In terms of applications, HME technique has been used to develop different dosage forms
for different drug delivery systems. These include sustained released tablets(9), pellets (10),
granules (11), transdermal dosage form (12), and implants (13). Furthermore, additional benefits can
be provided by HME over the traditional techniques, since it’s a solvent-free and continuous
process, and it has a low cost and a small footprint.
HME technique relies on three major steps, melting, mixing, and shaping. The mixture of
a polymer and an active pharmaceutical ingredient (API) passes through three zones. First, the
mixture is fed through the feeder and transferred to the melting zone by the barrels. In the
melting zone the mixture begins to soften, then moves to the mixing zone where the drug is
dispersed within the polymer. The shaping zone has the function of reducing the pulsation flow
and maintaining a uniform delivery rate throughout the die (Figure 1) (2).
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Figure 1(2). A schematic for the hot-melt extrusion process.

1.4. Active pharmaceutical ingredients:
1.4.1. Curcumin:
Curcumin is one of the major ingredients derived from turmeric (Curcuma Longa Linn).
For many years, curcumin was the preferred choice in home remedies to treat several diseases,
especially in Indian traditional medicine (14). In the last two decades, scientists have been
investigating the efficiency of curcumin against many diseases. Moreover, curcumin has shown
significant pharmacological impacts as an anti-cancer(15), anti-inflammatory, and anti-microbial
drug (16). However, it is rapidly metabolized by glucuronidation, which is the major metabolic
pathway that transforms curcumin into less active metabolites, dehydrocurcumin,
tetrahydrocucumin, and hexahydrocurcumin(19). Additionally, it is classified under class IV of the
biopharmaceutical classification system (low solubility and low permeability) (18). These
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disadvantages decrease the bioavailability of curcumin, and limiting its efficacy as a promising
drug (18).
The chemical structure of curcumin contains three essential functional groups. Two
phenolic ring systems containing methoxy functional groups and a seven-carbon linker that
contain a diketone moiety, as shown in figure 2. The diketone moiety undergoes keto-enol
tautomerism, and depending on the environment, either one can be the major tautomer (17).

Figure 2. The chemical structure of curcumin.

1.4.2. Piperine:
Piperine is the main component of black pepper (Piper nigrum Linn). It has been widely
used as a spicy flavor in food. Recently, a great deal of studies has shown that piperine has a
therapeutic potential as an anti-depressant, anti-inflammatory, antioxidant, and anti-cancer agent
(20, 21)

. Another important property of piperine that has been deeply investigated by scientists is

the ability of piperine to be used as a metabolic inhibitor (22). It has been reported that piperine
can increase the bioavailability of other drugs by inhibiting several metabolic enzymes, such as
cytochrome P-450 (CYP3A4, CYP2E1, CYP1B2, CYP1B1), UDP- glucanosyltransferases, and
aryl hydrocarbon hydroxylase (23) (24).
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1.5. Objectives:
The objective of this study was to increase the bioavailability of curcumin by enhancing
its solubility and decreasing its rapid metabolism. To achieve that, HME was used to prepare a
solid dispersion of curcumin and piperine utilizing the hydrophilic polymer (Soluplus®). Piperine
was incorporated as a metabolic inhibitor to protect curcumin from being extensively
metabolized. Important parameters such as the effect of extrusion temperature, loading capacity
of the polymer, the interaction between the drug and the polymer were evaluated.
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2. METHODOLOGY
2.1.Materials
Curcumin and piperine were purchased from Fisher Scientific (Fair Lawn, NJ, USA) and
Sigma-Aldrich (Milwaukee, WI, USA), respectively. Soluplus® was obtain as a gift from BASFSE (Ludwigshafen, Germany). All other chemicals and solvents were of analytical grade and
were purchased from Fisher Scientific (Fair Lawn, NJ, USA).

2.2.Methods
2.2.1. Hot-melt extrusion
Three physical mixtures were prepared with different ratio of the components (curcumin,
piperine, and Soluplus®, Table 5). The physical mixtures were blended using V-shell blender for
10 minutes (Patrtreson-Kelley twin shell dry blender). The resulting physical mixtures were
extruded using the co-rotating twin-screw extruder (11 mm twin screw extruder, Thermo Fisher
Scientific). The selected screw configuration consisted of four conveying zones and three mixing
zones, as seen in figure 3. Two different extrusion temperatures were applied for each
formulation (130 °C and 140 °C), with a screw speed of 75 rpm (Table 6).
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Table 5. Composition of the three formulations.
Formulation

Curcumin

Piperine

Soluplus®

F1

15%

5%

80%

F2

30%

10%

60%

F3

45%

15%

45%

Figure 3. Selected screw configuration.
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Table 6. Parameters of the hot-melt extrusion process.
Formulation

Temperature

Feeding rate

Screw speed

Torque

(°C)

(g/min)

(rpm)

(%)

F1

130

1

75

40 %

F1

140

1

75

25 %

F2

130

1

75

30 %

F2

140

1

75

22 %

F3

130

1

75

16 %

F3

140

1

75

15 %

2.2.2. Differential scanning calorimetry (DSC)
The physical state of the components before and after the extrusion process were
evaluated using differential scanning calorimetry (DSC) (TA instruments DSC 25 Discovery
series) with a heating rate of 10 °C /min ranging from 20 to 200 °C. The weights of the samples
were between 3 to 6 mg, and the weighed samples were placed in aluminum pans. Trios software
was used to analyze the thermograms of the samples.

2.2.3. Scanning electron microscopy (SEM)
The surface morphologies of all extrudates were characterized using the scanning
electron microscope (SEM, JEOL, JSM-7200). The samples were mounted on carbon pad placed
on aluminum stub and sputter-coated with gold. The process was conducted with an accelerating
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voltage of 5 kV.

2.2.4. Fourier transform infrared spectroscopy (FTIR)
Fourier transform infrared spectroscopy (Agilent Cary 630 with a DTGS detector) was
performed to study the interaction between the components. Weighed samples (2–4 mg) were
analyzed using a scanning range from 1000 to 4000 cm-1 with a resolution of 1 cm-1.

2.2.5. Drug content
Known amounts of compounds from each formulation F1 (130 °C and 140 °C), F2 (130
°C and 140 °C), and F3 (130 °C and 140 °C) were dissolved in acetonitrile, then the solutions
were placed on the vortex stirrer (Scientific industries vortex genie-120V) for one minute for
good mixing. Standard calibration curves were performed with r 2 between 0.99 to 1. High
performance liquid chromatography (HPLC) consisting of a Waters 2695 separation Module and
Waters 2489 UV/Visible detector (Waters Technologies Corporation, Milford, USA) was used to
analyze the samples. The mobile phase was a mixture of 0.1% orthophosphoric acid in water and
acetonitrile (50:50 v/v). The chromatography was done using the Phenomenex C8 column (5
microns, 150 * 4.6 mm) and a flow rate of 0.8 mL/min with a 10 µL injection volume, and a
column temperature of 35 °C with a wavelength of 262 nm.

2.2.6. In-vitro drug release studies
In-vitro drug release studies were performed to evaluate the release profiles for the
formulations F1 (130 °C and 140 °C), F2 (130 °C and 140 °C), and F3 (130 °C and 140 °C)
along with the pure compounds (curcumin and piperine). The study was conducted using USP
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apparatus II, and a dissolution medium of 900 mL 0.1 N HCL (pH 1.2) with 0.1% sodium lauryl
sulfate (SLS) and a paddle speed of 100 rpm. The temperature of the medium was maintained at
37 °C during the study. A sample volume of 2 ml was taken at predetermined time points 15, 30,
45, 60, 90, 120, 150, and 180 min, and 2 mL of fresh medium was added each time to maintain
the volume at 900 mL. The samples were centrifuged for 10 min at 13,000 rpm, then the
supernatants were analyzed using the HPLC (25). All dissolution experiments were conducted in
triplicates. Similarity factors were calculated to compare the drug release profiles of the different
formulations. Moreover, the drug release kinetic was evaluated using an open source software
KinetDS.

2.2.7. Stability studies
A 3-month stability study was performed under the conditions of 25 °C and 60%
humidity. Tests were conducted at months 0 and 3. A portion from each extrudate was packed in
a glass vial and stored in the stability chamber. The study was conducted to evaluate the integrity
of the formulations during the storage time, utilizing DSC, drug content, and drug release profile.
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3. RESULTS AND DISCUSSION

3.1. Hot-melt extrusion
According to the standard HME procedure, the starting extrusion temperature preferred to
be above the polymer glass transition temperature by 40 degrees and lower than the drug
degradation temperature. Since the glass transition (Tg) for Soluplus® was 75 °C, and the
melting points for curcumin and piperine were 180 °C and 130 °C, respectively, the first starting
temperature was chosen to be 115 °C. Unfortunately, at both 115 °C and 120 °C extrusion
temperatures, the physical mixture was stuck inside the instrument. To adjust the extrusion
temperature, 130 °C was selected to be the extrusion temperature. On the other hand, 140 °C was
also used to evaluate the effect of the extrusion temperature on the physicochemical properties of
the formulations. Other extrusion parameters such as the feeding rate and the screw speed were
kept the same during the extrusion process for all formulations (Table 6).

The extrudates’ appearances shown in figure 4, F1 and F2 had light red, and brown red
color, respectively. Whereas, the appearance of F3 was different, having a brown black color.
This indicates that only a small percent of the drug was dissolved in the matrix for F3 due to high
drug loading (45% curcumin and 15% piperine).
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A

B

E

C

D

F

Figure 4. Physical appearance of the extrudates (A) F1 (5%Pip, 15%Cur, 80%Solu with
temperature 130 °C), (B) F1 (5%Pip, 15%Cur, 80%Solu with temperature 140 °C), (C) F2
(10%Pip, 30%Cur, 60%Solu with temperature 130 °C), (D) F2 (10%Pip, 30%Cur, 60%Solu with
temperature 140 °C), (E) F3 (15%Pip, 45%Cur, 40%Solu with temperature 130 °C), (F) F3
(15%Pip, 45%Cur, 40%Solu with temperature 140 °C).

3.2. Differential scanning calorimetry (DSC)
Thermal analysis was performed to evaluate different parameters, including the melting
points of curcumin and piperine, and the glass transition temperature for Soluplus®. Moreover,
DSC was conducted to investigate the physical state of the drugs, physical mixtures, and
extrudates. Thermograms of curcumin and piperine revealed endothermic peaks at temperature
132 °C and 180 °C, respectively. The endothermic peaks indicate that curcumin and piperine are
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existing in crystal states. Moreover, the glass transition temperature for Soluplus® was at 75 °C
(Figure 5).
It can be observed from figure 6 that the physical mixtures’ thermograms for
formulations F2 and F3 have two endothermic peaks at temperatures 110 °C and 160 °C. Both
peaks are lower than the melting points of pure piperine and curcumin (132 °C and 180 °C,
respectively), implying that fractions of piperine and curcumin still exist in crystalline form. The
intensities of the peaks are larger for F3 than F2, due to the increase in the drug loading.
Additionally, the physical mixture of formulation F1 showed only one peak at 170 °C for
curcumin. Thermal analysis of Formulations F1 (130 °C and 140 °C), F2 (130 °C and 140 °C),
and F3 (130 °C and 140 °C) showed only one peak at around 70 °C, corresponding to the
polymer glass transition temperature. The absence of the endothermic peaks in the thermogram
of the extrudates is due to the change in their physical states, form crystalline to amorphous.
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Figure 5. Thermogram of pure curcumin, pure piperine, and Soluplus®.

Figure 6. Thermogram of the physical mixtures of the three formulations, F1 (5%Pip, 15%Cur,
80%Solu), F2 (10%Pip, 30%Cur, 60%Solu), and F3 (15%Pip, 45%Cur, 40%Solu).
17

Figure 7. Thermogram of the three formulations, F1 (130 °C and 140 °C), F2 (130 °C and 140
°C), and F3 (130 °C and 140 °C).

3.3. Scanning electron microscopy
The surface morphology of F1 with drug loading (5% piperine, 15% curcumin, 80%
Soluplus®), and F2 (10% piperine, 30% curcumin, 60% Soluplus®) showed smooth surfaces with
absent of crystals. These images suggested the solubilization of the drugs within the polymeric
carrier at an amorphous form (Figures 8 and 9). Moreover, crystal appearance was evident in F3,
due to high drug loading (15% piperine, 45% curcumin, 40% Soluplus®) that exceeded the
polymeric carrier capacity, as seen in figure 10. SEM images for F3 were inconsistent with DSC
thermal analysis, which showed no appearance of drug crystalline peaks in the extrudates. This
could be due to the fact that the polymer has a transition glass temperature of 75 °C, which is
lower than the drugs’ melting points. Consequently, the polymer will soften and solubilize the
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drugs before reaching their melting points, preventing the appearance of crystalline peaks.
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Figure 8. SEM images for all formulations. A- F1 with extrusion temperature 130 °C, and B- F1
with extrusion temperature 140 °C. C- F2 with extrusion temperature 130 °C, and D- F2 with
extrusion temperature 140 °C. E- F3 with extrusion temperature 130 °C, and F- F3 with
extrusion temperature 140 °C.

3.4. Fourier transforms infrared spectroscopy
Hydrogen bonding interactions between the components could facilitate the solubilization
and enhance the stability for the formulations. FTIR was performed to determine the presence of
hydrogen bonds between the components. The FTIR spectra of both curcumin and Soluplus®
revealed sharp peaks at 1626 for carbonyl group, which were broadened in all formulation
implying the presence of hydrogen bonds. Additionally, the disappearance of the hydroxyl peak
at 3507 in curcumin and the methylenedioxy peak at 2940 in peiperine support the formation of
hydrogen bonds, as seen in Figure 11.
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A

B

21

C

Figure 9. FTIR analysis of the three formulations, A- F1 with extrusion temperatures 130 °C,
and 140 °C. B- FT-IR analysis for formulation F2 with extrusion temperatures 130 °C, and 140
°C. C- FT-IR analysis for formulation F3 with extrusion temperatures 130 °C, and 140 °C.

3.5. Drug content
Three weighed samples (25–40 mg) from each formulation F1 (130 °C and 140 °C), F2
(130 °C and 140 °C), and F3 (130 °C and 140 °C) were dissolved in 20 mL of acetonitrile. The
samples were analyzed using HPLC at a wavelength of 262 nm. The results showed that all
formulations have drug contents with the range of 80% to 100% for both curcumin and piperine
(Tables 7 and 8).
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Table 7. The percent drug content of curcumin.
Formulation

Drug content %

F1 with extrusion temperature 130 °C

100

F1 with extrusion temperature 140 °C

98

F2 with extrusion temperature 130 °C

85

F2 with extrusion temperature 140 °C

100

F3 with extrusion temperature 130 °C

92

F3 with extrusion temperature 140 °C

99

Table 8. The percent drug content of piperine.
Formulation

Drug content %

F1 with extrusion temperature 130 °C

96

F1 with extrusion temperature 140 °C

100

F2 with extrusion temperature 130 °C

80

F2 with extrusion temperature 140 °C

98

F3 with extrusion temperature 130 °C

94

F3 with extrusion temperature 140 °C

98

3.6. In-vitro drug release studies
The release study for pure curcumin showed a negligible amount of drug release, 13%.
The deficiency in curcumin release profile is due to its low aqueous solubility.
The release profiles of curcumin in F1, F2, and F3, with both extrusion temperatures (130 °C and
140 °C), have significantly increased for up to 9-folds compared to the pure drug. When
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analyzing the release profiles of curcumin, F1 with the extrusion temperatures (130 °C and 140
°C) had a percent release of 93%, which was the highest (Figure 12). Moreover, the percent
release in F2 with both extrusion temperature (130 °C and 140 °C) were 86% and 77%,
respectively (Figure 13). The highest drug loading (45%) F3 had the lowest release profile
compared to F1 and F2, 65% for both extrusion temperatures (130 °C and 140 °C), as seen in
figure 14. The increase of drug loading within the formulations affected the drug release,
implying that a portion of the drug is still in the crystal form or did not completely dissolve
within the carrier.
Piperine had different release profiles, where F1 with both extrusion temperatures (130
°C and 140 °C) showed percent releases of 100% and 94%, respectively, compared to pure
piperine (75%). Whereas, F2 and F3 with both extrusion temperatures (130 °C and 140 °C) have
not showed a significant improvement in the release profiles.
Both curcumin and piperine had improved drug release profiles for all HME
formulations. This is a consequence of particle size reduction and the resulting increase in
surface area. Moreover, low energy is required to break the crystal lattice to release the drug
during the dissolution step.
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F1-130 °C Drug Release Study
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F1-140 °C Drug Release Study
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Figure 10. The release profiles for F1 formulations, with extrusion temperatures of A- 130 °C,
and B- 140 °C in a medium with pH 1.2 using apparatus II with 100 rpm, at 37 °C for 3 h.
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Figure 11. The release profiles for F2 formulations, with extrusion temperatures of A- 130 °C,
and B- 140 °C in a medium with pH 1.2 using apparatus II with 100 rpm, at 37 °C for 3 h.
26

A

F3-130 °C Drug Release Study
100
90

% Drug Release

80
70

60
50
40
30
20
10
0
0

20

40

60

80

100

120

140

160

180

Time (minute)
Pure Curcumin

B

Pure Piperine

Cur F3-130 °C

Pip F3-130 °C

F3-140 °C Drug Release Study
100
90

% Drug Release

80
70
60
50

40
30
20
10
0
0

20

40

60

80

100

120

140

160

180

Time (minute)
Pure Curcumin

Pure Piperine

Cur F3-140 °C

Pip F3-140 °C

Figure 12. The release profiles for F3 formulations, with extrusion temperatures of A- 130 °C,
and B- 140 °C in a medium with pH 1.2 using apparatus II with 100 rpm, at 37 °C for 3 h.
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Similarity factors were calculated to compare the drug release profiles between the
formulations prepared with different extrusion temperatures (equation 2) (26). As shown in tables
9, the similarities in the dissolution profiles had f2 values higher than 50, and closer to 100.
Based on this result, the difference in temperature showed no impact on the release of the drugs.

F2= 50.log{[1+(1/n) ∑ (Rt-Tt)2}]-05

(Equation 2)

Table 9. Similarity factor calculation for curcumin and piperine.
Curcumin

Piperine

Formulation
f2

similarity

f2

similarity

F1 with extrusion temperature 130 °C
&
F1 with extrusion temperature 140 °C

67

Yes

84.5

Yes

F2 with extrusion temperature 130 °C
&
F2 with extrusion temperature 140 °C

69

Yes

77.5

Yes

F3 with extrusion temperature 130 °C
&
F3 with extrusion temperature 140 °C

75

Yes

94

Yes

Curcumin release kinetics were determined by regression coefficient (R2) for each
formulation utilizing several release models, as seen in tables 10-12. The results indicate that
curcumin releases were followed Korsmeyer-Peppas, Weibull, and Hill equation (Tables 10-12).
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Table 10. F1 dissolution kinetic calculations
Model

F1- 130 °C

F1- 140 °C

Zero order

0.6227

0.6291

First order

0.2298

0.2305

Korsmeyer-Peppas

0.9961

0.9962

Weibull

0.9988

0.9987

Hickson-Crowell

0.3773

0.3826

Higuchi

-2.9481

-2.8870

Hill equation

0.9998

0.9999

Table 11. F2 dissolution kinetic calculations
Model

F2- 130 °C

F2- 140 °C

Zero order

0.6477

0.6546

First order

0.2302

0.2302

Korsmeyer-Peppas

0.9961

0.9961

Weibull

0.9983

0.9978

Hickson-Crowell

0.3831

0.3837

Higuchi

-2.9202

-2.9018

Hill equation

0.9998

0.9993
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Table 12. F3 dissolution kinetic calculations
Model

F3- 130 °C

F3- 140 °C

Zero order

0.7675

0.8325

First order

0.2368

0.2413

Korsmeyer-Peppas

0.9971

0.9976

Weibull

0.9982

0.9987

Hickson-Crowell

0.4446

0.4868

Higuchi

-2.3905

-2.1058

Hill equation

0.9993

0.9996

3.7. Stability study
Three months of stability study was conducted 25 °C, and 60% humidity. A portion from
each extrudate was packed in a glass vial and stored in the stability chamber. Tests were
applied at months 0, and 3. The results from the release studies, drug content, and thermal
analysis (DSC) showed no difference between the initial formulations and third month. It can
deduce that’s all formulations were maintained stable physically and chemically during the
three months with no sign of degradation or recrystallization.
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4. CONCLUSION
Curcumin and piperine formulation were successfully developed utilizing hot
melt extrusion technique. Furthermore, the enhancement in curcumin dissolution and
release from the dosage form was achieved up to 9-folds compared to the pure drugs. It
can be observed from the stability study that’s Soluplus® showed a significant impact as a
recrystallization inhibitor by maintaining the integrity of the formulations for three
months. Moreover, there was no impact of the extrusion temperatures (130 °C, 140 °C)
on the physicochemical properties of the formulations. In vivo study will be conducted to
study and evaluate the effect of piperine as a bioavailability enhancer for curcumin.
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